Edition:
United States

Sumitomo Dainippon Pharma Co Ltd (4506.D)

4506.D on Dusseldorf Stock Exchange

10.70EUR
20 Sep 2017
Change (% chg)

€-0.08 (-0.70%)
Prev Close
€10.77
Open
€10.70
Day's High
€10.70
Day's Low
€10.70
Volume
0
Avg. Vol
0
52-wk High
€17.90
52-wk Low
€10.65

Chart for

About

Sumitomo Dainippon Pharma Co., Ltd., formerly Dainippon Sumitomo Pharma Co.,Ltd., is a pharmaceutical company. The Japan division manufactures and sells ethical and general use drugs. The North America division manufactures, develops, purchases and sells ethical drugs through its consolidated subsidiaries. The China division... (more)

Overall

Beta: 0.76
Market Cap(Mil.): ¥588,494.31
Shares Outstanding(Mil.): 397.90
Dividend: 9.00
Yield (%): 1.22

Financials

  Industry Sector
P/E (TTM): -- 31.91 16.25
EPS (TTM): -- -- --
ROI: -- 15.14 14.87
ROE: -- 16.37 13.89

BRIEF-Sumitomo Dainippon Pharma U.S.-based unit enters agreement to divest asthma and allergy products to Covis pharma

* Says its U.S.-based unit Sunovion Pharmaceuticals Inc. has entered into a definitive agreement to divest the U.S. market rights of Sunovion’s three ciclesonide products to Covis Pharma B.V. on July 13(US Eastern Time)

Jul 13 2017

BRIEF- Sumitomo Dainippon Pharma unit Sunovion announces FDA acceptance for review of new drug application resubmission for SUN-101

* Says its U.S.-based unit Sunovion Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the New Drug Application for SUN-101/eFlow® (glycopyrrolate) for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD)

Jul 02 2017

BRIEF- Sumitomo Chemical unit Sumitomo Dainippon Pharma announces unblinding of phase 3 study of Napabucasin

* Says its unit Sumitomo Dainippon Pharma Co Ltd announced today that the company decided to unblind the BRIGHTER study, a phase 3 global study in patients with gastric and gastro-esophageal junction (GEJ) cancer of napabucasin, an investigational cancer stemness inhibitor, based on a recommendation by the study’s independent Data and Safety Monitoring Board (DSMB), following a pre- specified interim analysis

Jun 25 2017

BRIEF- Sumitomo Dainippon Pharma announces application of International Financial Reporting Standards

* Says it will apply International Financial Reporting Standards (IFRS) as the new accounting method, to replace the current Japan-Generally Accepted Accounting Principles

May 29 2017

BRIEF-Sumitomo Dainippon Pharma unit receives Complete Response Letter from FDA for SUN-101/eFlow® New Drug Application for chronic obstructive pulmonary disease

* Says its US-based unit Sunovion Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for SUN-101/eFlow®(glycopyrrolate) for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD),including chronic bronchitis and/or emphysema, on May 26 (US Eastern time)

May 28 2017

BRIEF-Sumitomo Dainippon Pharma looks to expand applications of drug candidate Dasotraline - Nikkei

* Sumitomo Dainippon Pharma Co Ltd looks to expand the applications of its drug candidate dasotraline - Nikkei

Mar 24 2017

Earnings vs. Estimates